|
14 Jan 2021 |
Vor Announces FDA Clearance of IND Application for VOR33
|
|
13 Jan 2021 |
Cytovia Therapeutics Partners with National Cancer Institute to Develop Novel Gene-Edited, iPSC-Derived GPC3 CAR NK Cells for the Treatment of Solid Tumors
|
|
13 Jan 2021 |
KSQ Therapeutics and Takeda Enter Broad Strategic Collaboration to Research, Develop and Commercialize Novel Immuno-Oncology Therapies
|
|
13 Jan 2021 |
Jasper Therapeutics and Graphite Bio Announce Collaboration to Evaluate JSP191 as Conditioning Regimen for Novel Gene Replacement Therapy in Patients with XSCID
|
|
13 Jan 2021 |
Daiichi Sankyo Announces the Results Summary of Phase 1/2 Clinical Trial in Japan for DS-5141
|
|
12 Jan 2021 |
Verve Therapeutics Announces Data Demonstrating Durable LDL Cholesterol Lowering After a One-Time Gene Editing Treatment in Non-Human Primates
|
|
12 Jan 2021 |
Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study
|
|
11 Jan 2021 |
Editas Medicine Announces the FDA has Cleared Initiation of the EDIT-301 Clinical Trial
|
|
11 Jan 2021 |
Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology
|
|
11 Jan 2021 |
Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform
|
|
11 Jan 2021 |
Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME and Provides 2021 Business Outlook
|
|
11 Jan 2021 |
EXUMA Biotech Announces Collaboration with Moffitt Cancer Center for the Development of a Rapid-Point-Of-Care SC CAR-T Program
|
|
11 Jan 2021 |
Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study
|
|
11 Jan 2021 |
Single Dose of Rexlemestrocel-L Provides Substantial and Durable Reduction in Heart Attacks, Strokes and Cardiac Death in Patients With Chronic Heart Failure
|
|
11 Jan 2021 |
BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set
|
|
11 Jan 2021 |
Lysogene Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene Therapy Clinical Trial in the UK with LYS-GM101 for the Treatment of GM1 Gangliosidosis
|
|
10 Jan 2021 |
Ultragenyx Announces Progress Across Broad Gene Therapy Portfolio and Positive Longer-Term Data from Multiple Phase 1/2 Gene Therapy Studies
|
|
09 Jan 2021 |
Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
|
|
08 Jan 2021 |
Oncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell Therapies
|
|
08 Jan 2021 |
Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
|
|
08 Jan 2021 |
Exacis Biotherapeutics Announces Its Launch and mRNA Technology In-Licensing For Targeted CAR-NK And CAR-T Cell Cancer Therapies
|
|
07 Jan 2021 |
BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson's Disease
|
|
07 Jan 2021 |
Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy
|
|
07 Jan 2021 |
ArsenalBio Announces Multi-Program Discovery Collaboration with Bristol Myers Squibb to Advance Next-Generation T cell Therapies for Solid Tumors
|
|
07 Jan 2021 |
Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
|
